Assertio Holdings Inc (ASRT)
0.7824
-0.08
(-9.61%)
USD |
NASDAQ |
Apr 25, 16:00
0.7824
0.00 (0.00%)
After-Hours: 20:00
Assertio Holdings SG&A Expense (Quarterly): 23.96M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 23.96M |
September 30, 2023 | 21.00M |
June 30, 2023 | 16.77M |
March 31, 2023 | 16.90M |
December 31, 2022 | 13.70M |
September 30, 2022 | 11.90M |
June 30, 2022 | 10.54M |
March 31, 2022 | 10.64M |
December 31, 2021 | 11.26M |
September 30, 2021 | 9.013M |
June 30, 2021 | 24.04M |
March 31, 2021 | 8.324M |
December 31, 2020 | 21.27M |
September 30, 2020 | 27.61M |
June 30, 2020 | 28.13M |
March 31, 2020 | 27.31M |
December 31, 2019 | 22.95M |
September 30, 2019 | 36.12M |
June 30, 2019 | 24.76M |
March 31, 2019 | 25.04M |
December 31, 2018 | 25.47M |
September 30, 2018 | 33.41M |
June 30, 2018 | 31.31M |
March 31, 2018 | 29.03M |
December 31, 2017 | 48.32M |
Date | Value |
---|---|
September 30, 2017 | 48.85M |
June 30, 2017 | 50.01M |
March 31, 2017 | 48.52M |
December 31, 2016 | 48.46M |
September 30, 2016 | 51.57M |
June 30, 2016 | 51.90M |
March 31, 2016 | 52.56M |
December 31, 2015 | 58.34M |
September 30, 2015 | 49.06M |
June 30, 2015 | 57.41M |
March 31, 2015 | 34.54M |
December 31, 2014 | 28.96M |
September 30, 2014 | 27.08M |
June 30, 2014 | 32.57M |
March 31, 2014 | 32.52M |
December 31, 2013 | 27.47M |
September 30, 2013 | 26.37M |
June 30, 2013 | 25.37M |
March 31, 2013 | 25.96M |
December 31, 2012 | 24.02M |
September 30, 2012 | 26.83M |
June 30, 2012 | 25.02M |
March 31, 2012 | 21.77M |
December 31, 2011 | 21.54M |
September 30, 2011 | 21.47M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
8.324M
Minimum
Mar 2021
36.12M
Maximum
Sep 2019
19.27M
Average
21.00M
Median
Sep 2023
SG&A Expense (Quarterly) Benchmarks
Ocular Therapeutix Inc | 17.27M |
Cormedix Inc | 13.38M |
Verastem Inc | 8.637M |
Puma Biotechnology Inc | 19.82M |
BioVie Inc | 2.254M |